Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart J Pocock

Showing results (161-170 of 349) with videos related to

Pageof 35
Sort By:
European Journal of Heart Failure|July 4, 2015
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)Jane A Cannon, Timothy J Collier, Li Shen, et al.
American Heart Journal|November 19, 2011
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programCono A Ariti, John G F Cleland, Stuart J Pocock, et al.
European Heart Journal|March 23, 2017
Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivorsLaura Pasea, Sheng-Chia Chung, Mar Pujades-Rodriguez, et al.
European Heart Journal|July 30, 2025
Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fractionMasatake Kobayashi, Antoni Bayes-Genis, Kevin Duarte, et al.
European Journal of Heart Failure|June 17, 2022
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-ReducedFaiez Zannad, João Pedro Ferreira, John Gregson, et al.
The Canadian Journal of Cardiology|July 13, 2024
Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic ApproachesJohn W Eikelboom, Qilong Yi, William F McIntyre, et al.
JAMA Cardiology|October 2, 2024
Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical TrialMartino Martinelli-Filho, José A Marin-Neto, Mauricio Ibrahim Scanavacca, et al.
Circulation|October 23, 2020
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-ReducedFaiez Zannad, João Pedro Ferreira, Stuart J Pocock, et al.
International Journal of Cardiology|November 13, 2020
Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia studyJuan Zhou, Chee Tang Chin, Xin Huang, et al.
European Journal of Heart Failure|February 24, 2007
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programmeNathaniel M Hawkins, Duolao Wang, John J V McMurray, et al.
Pageof 35

Showing results (161-170 of 349) with videos related to

Sort By:
Pageof 35
European Journal of Heart Failure|July 4, 2015
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)Jane A Cannon, Timothy J Collier, Li Shen, et al.
American Heart Journal|November 19, 2011
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programCono A Ariti, John G F Cleland, Stuart J Pocock, et al.
European Heart Journal|March 23, 2017
Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivorsLaura Pasea, Sheng-Chia Chung, Mar Pujades-Rodriguez, et al.
European Heart Journal|July 30, 2025
Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fractionMasatake Kobayashi, Antoni Bayes-Genis, Kevin Duarte, et al.
European Journal of Heart Failure|June 17, 2022
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-ReducedFaiez Zannad, João Pedro Ferreira, John Gregson, et al.
The Canadian Journal of Cardiology|July 13, 2024
Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic ApproachesJohn W Eikelboom, Qilong Yi, William F McIntyre, et al.
JAMA Cardiology|October 2, 2024
Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical TrialMartino Martinelli-Filho, José A Marin-Neto, Mauricio Ibrahim Scanavacca, et al.
Circulation|October 23, 2020
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-ReducedFaiez Zannad, João Pedro Ferreira, Stuart J Pocock, et al.
International Journal of Cardiology|November 13, 2020
Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia studyJuan Zhou, Chee Tang Chin, Xin Huang, et al.
European Journal of Heart Failure|February 24, 2007
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programmeNathaniel M Hawkins, Duolao Wang, John J V McMurray, et al.
Pageof 35